Good morning, everyone. Here is my Monday round up of deal news across MedTech and Biotech last week. News includes obesity, cardiology, genetics, and more. Congratulations to all involved and let me know if I have missed anything.
đź””Novo Nordisk inks $1B biobucks Lexicon Pharmaceuticals obesity deal after seeing preclinical prospect shine with semaglutide
đź””Supira Medical has raised $120 million to complete the clinical development of its temporary heart pump, designed for patients undergoing high-risk cardiac procedures or suffering from shock.
🔔Cardio-focused company Kardigan is sewing a new digital data platform into its R&D patchwork through the acquisition of heart health tech firm Prolaio.
đź””A New Jersey-based biotech is looking to become the main character in the age-related macular degeneration field. Character Biosciences has landed a $93 million series B to progress its precision medicine candidates through clinical development.
🔔Merck & Co. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein(a) (Lp(a)) inhibitor.
🔔Kaken Pharmaceutical will hand Alumis $40 million in the near term for the rights to develop a late-stage tyrosine kinase 2 (TYK2) inhibitor as a dermatology treatment in Japan.
đź””Epicrispr Biotechnologies Raises $68M in Series B Financing, Prepares to Launch Clinical Trial
🔔Eye care giant Alcon appears to have gained the upper hand in the ongoing power struggle with Aurion Biotech by securing a majority stake in the clinical-stage company and replacing its CEO.
đź””Hubble Therapeutics LLCÂ a patient-focused biotechnology company developing a gene therapy to cure pediatric blindness, announces the successful closing of a $7.3 million Series A funding round, which will advance its lead candidate, HUB-101, into human clinical trials.
đź””Sanofi SA announced that it will acquire Dren Bio Inc’s bispecific myeloid cell engager DR-0201 for upfront US$600m and US$1.3bn in milestones
🔔Leuven-based Augustine Therapeutics NV will use the proceeds from a €77.7m in Series A financing to advance its preclinical HDAC6 inhibitor AGT-100216 for the treatment of Charcot-Marie-Tooth (CMT) disease to Phase I testing.
===============
Newton Colmore is a specialist search firm and we connect exceptional engineering and scientific talent with impactful companies, globally.
hashtagmedicaldevices hashtagmedtech hashtagbiotech hashtagtherapeutics hashtagdrugdiscovery